NAMPT and melanoma: We placed particular emphasis on Daporinad, a NAMPT inhibitor with previously reported antitumor activity and favorable safety profiles in early-phase clinical trials for refractory B-cell chronic lymphocytic leukemia and advanced melanoma [46,47,48,49].